“This is a showdown about whether the most valuable patents in the entirety of the patent system are valid,” Professor Jacob Sherkow said of the patent feud between Amgen and rivals Sanofi and Regeneron that has reached the U.S. Supreme Court. Their decision in the case could have long-ranging implications for the pharmaceutical industry.
Read more on the case at Biopharma Dive.